Codon-Specific KRAS Mutations Predict Survival Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer

Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil, researchers identified KRAS codon G12 mutations as a potential biomarker of resistance.